Loading...
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Campbell, Ross T. Jhund, Pardeep S. Castagno, Davide Hawkins, Nathaniel M. Petrie, Mark C. McMurray, John V.J.
Campbell, Ross T.
Jhund, Pardeep S.
Castagno, Davide
Hawkins, Nathaniel M.
Petrie, Mark C.
McMurray, John V.J.
Abstract
Examination of patients with reduced and preserved ejection fraction in the DIG (Digitalis Investigation Group) trials and the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) trials provides comparisons of outcomes in each of these types of heart failure. Comparison of the patients in these trials, along with the I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function Trial), with patients of similar age, sex distribution, and comorbidity in trials of hypertension, diabetes mellitus, angina pectoris, and atrial fibrillation provides even more interesting insights into the relation between phenotype and rates of death and heart failure hospitalization. The poor clinical outcomes in patients with heart failure and preserved ejection fraction do not seem easily explained on the basis of age, sex, comorbidity, blood pressure, or left ventricular structural remodeling but do seem to be explained by the presence of the syndrome of heart failure. (J Am Coll Cardiol 2012;60:2349–56) © 2012 by the American College of Cardiology Foundation
Keywords
heart failure, preserved ejection fraction, outcomes, reduced ejection fraction
Date
2012
Type
Journal article
Journal
Journal of the American College of Cardiology
Book
Volume
60
Issue
23
Page Range
2349-2356
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
Open access
License
File Access
Controlled